Results from a meta-analysis published in the Journal of Cancer suggested that following induction and consolidation treatments, minimal residual disease (MRD) positivity was associated with worse progression-free survival (PFS) and overall survival (OS) for patients with mantle cell lymphoma (MCL).
Based on these findings, the investigators recommended that MRD-based treatment strategies should continue to be explored in clinical trials and within real-world practice.
“MRD status after both induction therapy and consolidation therapy showed prognostic value,” wrote the study authors, who were led by Yu Zhou. “This may provide information for deciding timing of MRD assessment.”
For the purposes of this study, investigators searched various databases— including Pubmed, Embase, Web of Science, and the Cochrane Library—to extract and analyze patient characteristics, MRD…
